Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Cantor Fitzgerald Initiates Coverage On BioCryst Pharmaceuticals with Overweight Rating, Announces Price Target of $21
Cantor Fitzgerald analyst Brian Cheng initiates coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Overweight rating and announces Price Target of $21.
Analyzing BioCryst Pharmaceuticals’s Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert.
Unusual Options Activity Insight: BioCryst Pharmaceuticals
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1.
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D…
BioCryst Announces Designs For REDEEM-1 And REDEEM-2 Pivotal Trials With BCX9930 As Oral Monotherapy For Patients With PNH
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction…
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months.
Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third quarter.
BioCryst Pharmaceuticals Announces ORLADEYO Data To Be Presented At European Academy Of Allergy And Clinical Immunology Hybrid Congress
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress from July 10-12, 2021.
Durable
BioCryst Pharmaceuticals Granted U.S. Patent Titled ‘Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)’
https://clinicaltrials.gov/ct2/show/NCT04933721